Asahi Kasei Pharma filed for provisional injunctions against infringement of patent rights of “Teribone™ Injection”
April 28, 2022
Asahi Kasei Pharma Corp.
On April 21, 2022, Asahi Kasei Pharma Corp. (Head Office: Chiyoda-ku, Tokyo; President: Yoshikazu Aoki; hereinafter “Asahi Kasei Pharma”) filed an infringement litigation of patent rights with the Osaka District Court against Sawai Pharmaceutical Co., Ltd.
In this filing for the infringement litigation, Asahi Kasei Pharma claims infringement of its patent rights (Patent No. 6025881; FREEZE-DRIED PREPARATION CONTAINING HIGH-PURITY PTH AND METHOD FOR PRODUCING SAME) relating to “Teribone™ Injection” for osteoporosis and seeks injunctions preventing Sawai Pharmaceutical Co., Ltd. from manufacturing and selling its generic of “Teribone™ Injection” approved by the Minister of Health, Labor and Welfare on February 15, 2022, in Japan.
Asahi Kasei Pharma values intellectual property rights as important management resources, and will continue to protect its intellectual property through resolute action against infringement of its intellectual property rights.